Affini-T Therapeutics
Affini-T Therapeutics, based in Watertown, MA, develops TCR-based immunotherapies for solid tumors, focusing on oncogenic mutations such as KRAS and p53.
Services
Affini-T Therapeutics specializes in developing TCR-based immunotherapies to treat solid tumors. They employ two main therapeutic modalities, including bispecific T Cell Engagers and autologous TCR-T cell therapies. These services are focused on targeting oncogenic driver mutations, such as KRAS mutations which appear in 30% of all solid tumors. The company is also committed to conducting clinical trials and seeking marketing approvals from regulatory authorities like the U.S. FDA.
Therapeutic Platforms
Affini-T Therapeutics utilizes advanced platforms to enhance its therapeutic offerings. TAILOR™ is used for bespoke TCR discovery, enabling the identification of optimal T-cell receptors. TUNE™ focuses on engineering T cells to improve their efficacy and safety. THRIVE™ is dedicated to the manufacturing of cell products, ensuring the scalability and quality of their therapies. These platforms work together to create robust and effective immunotherapies.
Research and Development Initiatives
Affini-T Therapeutics has presented significant preclinical data from oncogenic driver programs, particularly targeting KRAS G12D and p53 R175H mutations. This research was showcased at the American Association for Cancer Research (AACR) Annual Meeting in 2024. The focus on these specific mutations aligns with the company's dedication to targeting oncogenic driver mutations in solid tumors, furthering their goal of developing impactful cancer therapies.
Location and Headquarters
Affini-T Therapeutics is headquartered at 100 Forge Road, Watertown, MA 02472. This location serves as the central hub for their research, development, and corporate activities, enabling them to coordinate efforts efficiently across various disciplines involved in their immunotherapy initiatives.